Pills from the crisis

Yesterday, at a meeting of the round table, on the prospects for the development of the Farmotsli, held as part of the annual exhibition, the influence of the global crisis on the pharmaceutical industry was discussed. “Pfizer has lost 40%of the cost of shares in six months, Israeli Teva in the last 10 days - 25%, other companies - from 10 to 30%,” said Mikhail Getman, chairman of the supervisory board of NP “National Pharmaceutical Inspectorate”.

Crisis and Russian companies did not go around. The quotes of Pharmstandart and Verofarma collapsed. The Russian company “Valenta” has already begun the sale of assets. At the same time, state support for domestic factories is not carried out.

The operational manager of the IMS International Analytical Company Maria Denisova cited the fact that today, when contacting Russia, 4.5 thousand MNN domestic plants are produced only 50. In the state program of additional drug support, domestic drugs make up only 5%, and in hospital procurement - 26%.

<< We are located at the very beginning of the crisis, which without urgent measures of domestic manufacturers next year will lead to the bankruptcy of the bulk of Russian factories, and the country's farmes to collapse, ”Mikhail Getman believes. << The question is not about additional investments today, we are talking about the existence of the industry as a whole and the drug, the expert said.“ The expert said. Years when only the one who came to the hospital with their medicines will be treated, is quite likely >>.

The general director of the Association of Russian Pharmaceutical Manufacturers, Viktor Dmitriev, told the “newspaper” correspondent that, according to his forecast, by 2010, no more than 20% of competitive companies from 360 license will be able to remain in the domestic pharmaceutical market. The way out, in his opinion, is still: not a single generic drug from importers should be purchased by the state, if there is a similar production in Russia.

Nevertheless, in line for the state farm farmprom, far from the first. The analyst of the Finams, Sergei Filchenkov, notes that since the main part of the domestic pharmaceutical industry is uncompetitive, everything will depend on the conjuncture and the cost of money. The possibility of long-term state investigations today may not look as indisputable as a year ago, when a 2020 strategy was developed. << The state’s help is needed by many, and the domestic pharmaceutical industry will not be a priority, ”the analyst believes.